49 results
8-K
EX-99.2
TRVN
Trevena Inc
15 May 23
Trevena Reports First Quarter 2023 Results and Provides Business Update
7:05am
- Tolerated in Ph1 Healthy Volunteer PK Study Well tolerated, with no SAEs across broad range of doses Predictable PK: dose - proportional between 0.1 mg to 30
8-K
EX-99.2
TRVN
Trevena Inc
30 Mar 23
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
7:06am
in the US 1 :
TRV250: Well - Tolerated in Ph1 Healthy Volunteer PK Study Well tolerated, with no SAEs across broad range of doses Predictable PK: dose
424B5
TRVN
Trevena Inc
17 Nov 22
Prospectus supplement for primary offering
9:49pm
announced the completion of our first-in-human Phase 1 study of TRV250. Data from this healthy volunteer study showed a favorable tolerability profile
8-K
EX-99.2
TRVN
Trevena Inc
9 Nov 22
Trevena Reports Third Quarter 2022 Results and Provides Business Update
7:05am
Every year in the US 1 :
TRV250: Well - Tolerated in Ph1 Healthy Volunteer PK Study Well tolerated, with no SAEs across broad range of doses
424B5
26wxy44e fva
29 Jul 22
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.2
pn7hphb
28 Jul 22
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
7:06am
8-K
EX-99.1
njfutg jhto0sqzm
20 Apr 22
Regulation FD Disclosure
5:11pm
8-K
EX-99.2
bseh5jrt
31 Mar 22
Trevena Reports Fourth Quarter and Full Year 2021 Results
7:04am
8-K
EX-99.1
etab5pdgs18vgrfop
16 Jun 21
Regulation FD Disclosure
4:08pm
8-K
EX-99.2
i7i4taphq95p ti
6 May 21
Trevena Reports First Quarter 2021 Results
7:05am
8-K
EX-99.2
vzprt 9n0apd8krplhh
9 Mar 21
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
7:02am
424B5
rlwef53vxk pss
31 Dec 20
Prospectus supplement for primary offering
4:57pm
424B5
lixex iim
13 Aug 20
Prospectus supplement for primary offering
12:00am
424B5
93p3387lt7mp8nwgajz
11 Aug 20
Prospectus supplement for primary offering
4:23pm